Correction: Clinical Laserthermia Systems nomination committee appointed
The press release as of December 22, 2023 regarding the appointment of Nomination Committee of Clinical Laserthermia Systems AB (the "Company" or CLS") in accordance with the guidelines for the Nomination Committee adopted at the Annual General Meeting on June 29, 2023, incorrectly stated Lars-Erik T. Eriksson as a member of the Committee, representing Elano AB. The correct member is Hans von Celsing, representing himself. Furthermore, Henrik Nilsson was incorrectly stated as representing himself. The correct statement is that Henrik Nilsson is representing Arne Håkansson. In addition, Khattar Group has been updated to Khattar Holdings Pte Ltd and the date September 30, 2023, at which time the shareholdings of the largest class A and B shareholders were established, has been added.
Dec 22, 2023 - The Nomination Committee of Clinical Laserthermia Systems AB (the "Company" or CLS") has been appointed in accordance with the guidelines for the Nomination Committee adopted at the Annual General Meeting on 29 June 2023.
Members of the Nomination Committee
The following persons have been appointed members of the Nomination Committee for the 2024 Annual General Meeting:
- Karl-Göran Tranberg, representing KG Tranberg Medical AB – largest owner of class A shares.
- Hans von Celsing, representing himself – second largest owner of class A shares.
- Navin Khattar, representing Khattar Holdings Pte Ltd – largest owner of class B shares.
- Henrik Nilsson, representing Arne Håkansson – second largest owner of class B shares.
The Nomination Committee consists of representatives of the two (2) largest Class A shareholders in terms of voting rights and the two (2) largest Class B shareholders, as per September 30, 2023.
Duties of the Nomination Committee
The Nomination Committee shall submit proposals for:
a) Chairman of the Annual General Meeting,
b) the number of members of the Board of Directors and the number of auditors;
c) fees and other remuneration to the members of the Board of Directors, members of the Board's various committees and fees to the auditors,
d) election of the Chairman of the Board of Directors and other members of the Board of Directors and election of auditors; and
e) changes to the instruction for the Nomination Committee.
The Nomination Committee shall notify the Company of its proposals no later than six weeks before the Annual General Meeting. In connection with the nomination committee announcing its proposals to the Company, the nomination committee shall also issue a statement containing the information to be published on the Company's website.
For more information, please contact:
Hans von Celsing, Chairman of the Board, Clinical Laserthermia Systems AB
Phone: +44 7788 418 141
E-mail: hvc@berkshireinvest.net
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB
For more information about CLS, please visit the Company's website: www.clinicallaser.se